Breathe Well Live Well
SurfKY News |
UofL Researchers to Examine Asthma Triggers in Older Adults
SurfKY News LOUISVILLE, Ky. (4/4/15) Although often considered a childhood health problem, asthma – a chronic inflammatory disease that causes recurrent cough, wheezing and chest tightness or shortness of breath – can cause serious illness for people age 60 and … |
View full post on asthma – Google News
The Courier-Journal |
UofL study to tackle asthma in older adults
The Courier-Journal “We know a great deal about asthma in children, but, really, not much has been done about asthma in the elderly,” said Barbara Polivka, a Shirley B. Powers Endowed Chair in Nursing at UofL. “We have an aging population and we know that asthma is … |
View full post on asthma – Google News
Newswise (press release) |
UofL Researchers to Examine Asthma Triggers in Older Adults
Newswise (press release) Newswise — LOUISVILLE, Ky. – Although often considered a childhood health problem, asthma – a chronic inflammatory disease that causes recurrent cough, wheezing and chest tightness or shortness of breath – can cause serious illness for people age 60 … |
View full post on asthma – Google News
 |
Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study.
BMJ Open. 2015;5(3):e006897
Authors: Palmer SC, Ruospo M, Campbell KL, Garcia Larsen V, Saglimbene V, Natale P, Gargano L, Craig JC, Johnson DW, Tonelli M, Knight J, Bednarek-Skublewska A, Celia E, Del Castillo D, Dulawa J, Ecder T, Fabricius E, Frazão JM, Gelfman R, Hoischen SH, Schön S, Stroumza P, Timofte D, Török M, Hegbrant J, Wollheim C, Frantzen L, Strippoli GF, DIET-HD Study investigators
Abstract
INTRODUCTION: Adults with end-stage kidney disease (ESKD) treated with haemodialysis experience mortality of between 15% and 20% each year. Effective interventions that improve health outcomes for long-term dialysis patients remain unproven. Novel and testable determinants of health in dialysis are needed. Nutrition and dietary patterns are potential factors influencing health in other health settings that warrant exploration in multinational studies in men and women treated with dialysis. We report the protocol of the “DIETary intake, death and hospitalisation in adults with end-stage kidney disease treated with HaemoDialysis (DIET-HD) study,” a multinational prospective cohort study. DIET-HD will describe associations of nutrition and dietary patterns with major health outcomes for adults treated with dialysis in several countries.
METHODS AND ANALYSIS: DIET-HD will recruit approximately 10?000 adults who have ESKD treated by clinics administered by a single dialysis provider in Argentina, France, Germany, Hungary, Italy, Poland, Portugal, Romania, Spain, Sweden and Turkey. Recruitment will take place between March 2014 and June 2015. The study has currently recruited 8000 participants who have completed baseline data. Nutritional intake and dietary patterns will be measured using the Global Allergy and Asthma European Network (GA(2)LEN) food frequency questionnaire. The primary dietary exposures will be n-3 and n-6 polyunsaturated fatty acid consumption. The primary outcome will be cardiovascular mortality and secondary outcomes will be all-cause mortality, infection-related mortality and hospitalisation.
ETHICS AND DISSEMINATION: The study is approved by the relevant Ethics Committees in participating countries. All participants will provide written informed consent and be free to withdraw their data at any time. The findings of the study will be disseminated through peer-reviewed journals, conference presentations and to participants via regular newsletters. We expect that the DIET-HD study will inform large pragmatic trials of nutrition or dietary interventions in the setting of advanced kidney disease.
PMID: 25795691 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Uncover California |
FDA Panel Recommends Asthma Treatment Approval for Adults Only
Pharmacy Times (registration) "We recognize the advisory committee's thoroughness in reviewing the data related to Breo Ellipta for asthma,” said Darrell Baker, senior vice president and head of GSK's Global Respiratory Franchise, in a press release. “We will continue to work … GSK And Theravance: Implications Of The Advisory Panel Decision Breo Ellipta receives Mixed Views from FDA Panel |
View full post on asthma – Google News
|
GSK's Breo for asthma? FDA panel says yes–but only in adults
FiercePharma Good news for GlaxoSmithKline ($GSK): An FDA panel of experts says the efficacy and safety data for blockbuster wannabe Breo support the asthma indication it's gunning for in adults 18 and older. When it comes to children aged 12 to 17, though? UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents U.S. Panel Backs Glaxo's Breo for Asthma in Adults, Not Kids FDA panel backs Glaxo asthma drug for adults, not adolescents |
View full post on asthma – Google News
Channel News Asia |
UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents
Reuters The panel voted 16-4 that Breo Ellipta should be approved for once daily treatment of asthma in adults 18 years and older. It voted 19-1 that the data did not support approval for use in children aged 12 to 17. The FDA is not obliged to follow the … U.S. Panel Backs Glaxo's Breo for Adults With Asthma, Not Kids GSK's Breo for asthma? FDA panel says yes–but only in adults FDA panel backs Glaxo asthma drug for adults, not adolescents |
View full post on asthma – Google News
Channel News Asia |
FDA panel backs Glaxo asthma drug for adults, not adolescents
Reuters The panel voted 16 to 4 that the product, Breo Ellipta, should be approved for once daily treatment of asthma in adults 18 years and older. It voted 19 to 1 that the data did not support approval for use in children aged 12 to 17. The FDA is not … Critical inspection of GlaxoSmithKline plc (ADR) (NYSE:GSK) by FDA … FDA panel backs Glaxo inhaler for adults, not adolescents GSK and Theravance Announce Outcome of US FDA Advisory Committee on … |
View full post on asthma – Google News
Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs).
Thorax. 2015 Feb 27;
Authors: Martineau AR, MacLaughlin BD, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, Kilpin K, McLaughlin D, Fletcher G, Mein CA, Hoti M, Walton R, Grigg J, Timms PM, Rajakulasingam RK, Bhowmik A, Rowe M, Venton TR, Choudhury AB, Simcock DE, Sadique Z, Monteiro WR, Corrigan CJ, Hawrylowicz CM, Griffiths CJ
Abstract
RATIONALE: Asthma exacerbations are commonly precipitated by viral upper respiratory infections (URIs). Vitamin D insufficiency associates with susceptibility to URI in patients with asthma. Trials of vitamin D in adults with asthma with incidence of exacerbation and URI as primary outcome are lacking.
OBJECTIVE: To conduct a randomised controlled trial of vitamin D3 supplementation for the prevention of asthma exacerbation and URI (coprimary outcomes).
MEASUREMENTS AND METHODS: 250 adults with asthma in London, UK were allocated to receive six 2-monthly oral doses of 3?mg vitamin D3 (n=125) or placebo (n=125) over 1?year. Secondary outcomes included asthma control test and St George’s Respiratory Questionnaire scores, fractional exhaled nitric oxide and concentrations of inflammatory markers in induced sputum. Subgroup analyses were performed to determine whether effects of supplementation were modified by baseline vitamin D status or genotype for 34 single nucleotide polymorphisms in 11 vitamin D pathway genes.
MAIN RESULTS: 206/250 participants (82%) were vitamin D insufficient at baseline. Vitamin D3 did not influence time to first severe exacerbation (adjusted HR 1.02, 95% CI 0.69 to 1.53, p=0.91) or first URI (adjusted HR 0.87, 95% CI 0.64 to 1.16, p=0.34). No clinically important effect of vitamin D3 was seen on any of the secondary outcomes listed above. The influence of vitamin D3 on coprimary outcomes was not modified by baseline vitamin D status or genotype.
CONCLUSIONS: Bolus-dose vitamin D3 supplementation did not influence time to exacerbation or URI in a population of adults with asthma with a high prevalence of baseline vitamin D insufficiency.
TRIAL REGISTRATION NUMBER: NCT00978315 (ClinicalTrials.gov).
PMID: 25724847 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Condition: Asthma
Interventions: Drug: Vapendavir; Drug: Vapendavir; Drug: Placebo
Sponsor: Biota Pharmaceuticals, Inc.
Recruiting – verified February 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days